For biologic-experienced patients hospitalized with acute severe ulcerative colitis, off-label, high-intensity doses of tofacitinib (Xeljanz) given with intravenous corticosteroids may have reduced ...

When anti–tumor necrosis factor-alpha (anti-TNF) treatment fails to achieve remission for patients with ulcerative colitis (UC), tofacitinib (Xeljanz) appears more effective sooner than vedolizumab ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with rheumatoid arthritis who ...

Treating rheumatoid arthritis with tofacitinib for 6 months is linked to an increase in lower limb muscle volume, especially in the thigh, and a rise in serum creatinine levels.

Please provide your email address to receive an email when new articles are posted on . Tofacitinib was similar to adalimumab and superior to placebo in treatment of patients with rheumatoid arthritis ...

Tofacitinib used as add-on therapy to corticosteroids helps reduce need for medical or surgical rescue therapy among patients with acute severe ulcerative colitis. Using tofacitinib as an adjunctive ...

Human colon, illustration. Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure. For patients with ulcerative colitis (UC) ...

The appraisal committee (section 5) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. Note that ...

The appraisal committee (section 5) considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tofacitinib Global Market Report 2023" - https://www.reportlinker ...